Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 272

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

Nebert, Daniel W · 1999 · Clinical Genetics

Abstract

Adverse drug reactions, due at least in part to interindividual variability in drug response, rank between the 4th and 6th leading causes of death in the USA. The field of ‘pharmacogenetics’, which is ‘the study of variability in drug response due to heredity’, should help in reducing drug‐caused morbidity and mortality. The recently coined term ‘pharmacogenomics’ usually refers to ‘the field of new drug development based on our rapidly increasing knowledge of all genes in the human genome’. However, the two terms – pharmacogenetics and pharmacogenomics – are often used interchangeably. A classification of more than five dozen pharmacogenetic differences is presented here. Most of these variations occur in drug‐metabolizing enzyme (DME) genes, with some presumed to exist in the DME receptor and drug transporter genes, and others have not yet been explained on a molecular basis. A method for unequivocally defining a quantitative phenotype (drug efficacy, toxicity, etc.) is proposed; this is where help from the clinical geneticist can be especially important. Our current appreciation of the degree of variability (including single‐nucleotide polymorphisms, SNPs) in the human genome is described, with emphasis on the need to prove that a particular genotype is indeed the cause of a specific phenotype; this topic has been termed ‘functional genomics’. Furthermore, the current amount of admixture amongst almost all ethnic groups will obviously make studies of gene–drug interactions more complicated, as will the withholding of ethnic information about DNA samples during any molecular epidemiologic study. DME genes and DME receptor and drug transporter genes can be regarded as ‘modifier genes’, because they influence disorders as diverse as risk of cancer, bone marrow toxicity resulting from occupational exposure, and Parkinson's disease; for this reason, the clinical geneticist, as well as the medical genetics counselor, should be knowledgeable in the rapidly expanding fields of pharmacogenetics and pharmacogenomics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1034/j.1399-0004.1999.560401.x

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 272

Metadata

Authors
Nebert, D. W.
Venue
Clinical Genetics
Publisher
Wiley
Published
1999-10
Volume
56
Issue
4
Pages
247-258
ISSN
  • 0009-9163 (ISSN-L)
  • 1399-0004
OpenAlex
W2024875479
Cited by
272
References
42
FWCI
18.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? https://app.cochat.ai/papers/10.1034/j.1399-0004.1999.560401.x
The paper
Nebert, D. W. (1999). Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics. https://doi.org/10.1034/j.1399-0004.1999.560401.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.